The present invention provides an oligonucleotide comprising the sequence 5′；-GGAACAGTTCGTCCATGGC-3′； (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100 mg to 350 mg of said oligonucleotide are administered to the subject on at least four separate occasions, wherein the separate occasions are each a week apart.
